GLO1 and obesity due to melanocortin 4 receptor deficiency: A recent clinical intervention study with a Glo-1 inducer produced a profound improvement of insulin resistance, improved glycemic control and arterial function and decreased vascular inflammation, suggesting that Glo-1 inducer therapeutics may have a future key role in alleviating complications of obesity.